Elli Papaemmanuil

Elli Papaemmanuil serves as the CEO and Scientific Co-founder of Isabl, where she also holds multiple roles including Director of Operations, Chief Business Officer (acting), Computational Biology Engineer, Computational Biologist, and Computational Biology Consultant. She is a leading expert in the application of AI to precision medicine, particularly in clinical oncology, and has published extensively in prestigious journals such as NEJM, Nature Genetics, and Nature Medicine. Her work has garnered over 43,000 citations, reflecting an h-index of 70. Additionally, she is a Biomedical and Software Engineer and the lead developer of the Isabl Platform. Elli also chairs the Department of Pediatrics at Memorial Sloan Kettering and is recognized as an early adopter and key opinion leader in precision genomic medicine, with an h-index of 112. She holds a professorship in Pathology and Genetics at Harvard Medical School and directs Cancer Genome Discovery at the Dana-Farber Cancer Institute. Furthermore, she co-founded Foundation Medicine, where her contributions have earned her an h-index of approximately 220.